Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims & Hers Health, Inc. is from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements made by the defendants about the company's business and operations lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline of August 25, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged misleading statements and failure to disclose critical information during the Class Period from April 29, 2025, to June 23, 2025 [1][2]. Company Summary - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, which included the sale of Novo Nordisk's FDA-approved Wegovy® on its platform [2]. - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, jeopardizing patient safety [5]. Legal Allegations - The lawsuit alleges that Hims & Hers made false and/or misleading statements and failed to disclose the risks associated with its collaboration with Novo Nordisk [2][5]. - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers due to these deceptive practices, leading to a significant drop in Hims & Hers' stock price by $18.26 per share, a decline of over 34%, closing at $45.00 per share [2]. Important Dates - The lead plaintiff motion deadline for investors is August 25, 2025 [3].

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against Hims & Hers Health, Inc. related to its partnership with Novo Nordisk, which may have misled investors regarding the nature of the collaboration and its implications for the company's stock value [1][4]. Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform in the U.S. and the U.K. [3]. Securities Fraud Claims - The complaint alleges that Hims & Hers made materially false and misleading statements and failed to disclose critical facts about its partnership with Novo Nordisk during the class period from April 29, 2025, to June 23, 2025 [4]. - Specifically, Hims & Hers allegedly engaged in deceptive promotion and sale of Novo Nordisk's Wegovy® weight loss drug, creating a substantial risk of termination of the partnership [4]. Partnership Details - On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, which included the immediate sale of a bundled offering of Wegovy® on its platform [5]. - However, on June 23, 2025, Novo Nordisk terminated the partnership, citing Hims & Hers' failure to comply with legal standards regarding the sale of compounded drugs and deceptive marketing practices that jeopardized patient safety [5]. Stock Impact - Following the termination announcement by Novo Nordisk, Hims & Hers' stock price dropped by $22.24 per share, representing a decline of 34.63%, closing at $41.98 per share on June 23, 2025 [5].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - Two complaints have been filed, with the first case titled Sookdeo v. Hims & Hers Health, Inc., and a subsequent similar complaint titled Yaghsizian v. Hims & Hers Health, Inc. [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, which contains semaglutide, on its platform [3]. - Allegations state that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk and claimed compliance with FDA regulations regarding the sale of compounded semaglutide [4]. Group 3: Stock Market Reaction - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and certain senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and asserted compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Following Novo Nordisk's announcement on June 23, 2025, to terminate its partnership with Hims & Hers due to these deceptive practices, Hims & Hers' stock price dropped by over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5]

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. due to allegations of deceptive promotion and sale of illegitimate versions of Wegovy®, leading to a significant drop in the company's stock price [2][3]. Group 1: Allegations and Impact - Hims & Hers Health, Inc. announced a collaboration with Novo Nordisk on April 29, 2025, to sell Wegovy® on its platform [2]. - Novo Nordisk terminated its partnership with Hims on June 23, 2025, citing deceptive practices that jeopardized patient safety, resulting in a 34.6% decline in Hims' share price, closing at $41.98 [2]. - The lawsuit claims that Hims failed to disclose its engagement in selling illegitimate versions of Wegovy® and the risk of partnership termination with Novo Nordisk [3]. Group 2: Legal Proceedings - Shareholders interested in leading the class action must file a motion by August 25, 2025, and can remain absent class members if they choose not to participate [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Company Overview - Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [2]. Legal Allegations - The class action lawsuit alleges that during the class period from April 29, 2025, to June 23, 2025, Hims & Hers made false or misleading statements and failed to disclose risks associated with its collaboration with Novo Nordisk [2]. - Specific allegations include the deceptive promotion and selling of illegitimate versions of Wegovy, which allegedly put patient safety at risk [2][3]. Partnership Termination - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing concerns over deceptive practices [3]. - Following this announcement, Hims & Hers' stock price fell by more than 34% [3]. Class Action Process - Investors who purchased Hims & Hers securities during the class period can seek appointment as lead plaintiff in the class action lawsuit [4]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [4]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases [5].

NEW YORK, July 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=155244&from=4 CLASS PERIOD: April 29, ...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers” or the “Company”) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares of Hims & Hers should contact the Firm prior to the August 25, 2025 lead pla ...